# A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)

> **NCT06761586** · PHASE1 · TERMINATED · sponsor: **Aurigene Discovery Technologies Limited** · enrollment: 9 (actual)

## Conditions studied

- Select Relapsed/Refractory Lymphoid Malignancies

## Interventions

- **DRUG:** AUR104

## Key facts

- **NCT ID:** NCT06761586
- **Lead sponsor:** Aurigene Discovery Technologies Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-12-12
- **Primary completion:** 2026-02-10
- **Final completion:** 2026-02-10
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Patient recruitment problems
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06761586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06761586, "A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06761586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*